(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Dependable Savvy Locks to Update Your Home Security - 2Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
- 3Far-right leader Le Pen to attend Brigitte Bardot's funeral
- 4Share your number one city visit transport that leaves a mark on the world wake up!
- 5Congolese rape survivors search in vain for medicine after USAID cuts
- What to watch for in weight loss drugs in 2026
- Vote in favor of the Top Vegetable for Senior
- Could the Star of Bethlehem have actually been a comet?
- Figure out How to Get the Most Familiar Drive for Seniors in SUVs
- Scientists have found an alarming environmental impact of vast data centers
- See the first close-up photos of the moon from NASA's Artemis II mission
- Overlooked infertility care should be part of national health services, says WHO
- Los Angeles County sees significant uptick in norovirus cases, officials say
- The most effective method to Pick The Right Speakers
